Written by Shannon Markus
Spoon Feed
Direct oral anticoagulants (DOACs) are widely used for preventing and treating thromboembolic disorders; however, serious bleeding remains a common side effect. This guideline document examines the current reversal strategies, their clinical efficacy, and the circumstances for their use.
Stopping the spill – a guide to DOAC reversal agents
The International Society on Thrombosis and Haemostasis has updated their guidance document on DOAC reversal, comparing reversal agents, reviewing clinical data, and providing guidance on indications. Though DOACs, such as apixaban, edoxaban, rivaroxaban (factor Xa inhibitors), and dabigatran (thrombin inhibitor), have a lower bleeding risk compared to vitamin K antagonists, serious bleeding remains a concern.
- Indications for reversal: Major bleeding, urgent surgery, or high bleeding-risk procedures. Reversal should NOT be used for elective or delayable surgery, stable GI bleeds, or asymptomatic high drug levels.
- Specific reversal agents: Idarucizumab (for dabigatran) and andexanet alfa (for factor Xa inhibitors), although the high cost of andexanet limits its use. New agents for factor XIa inhibitors are under development.
- Nonspecific reversal agents: Prothrombin complex concentrates (PCCs) like KCentra contain vitamin K-dependent factors and have low thromboembolic risk. Optimal dosing remains unclear. Activated PCC and recombinant factor VIIa (both typically used in select hemophilia patients), need more evidence. FFP and tranexamic acid may assist in massive bleeding but are not for routine reversal.
- Reversal Agent Comparisons and Risks: A major reversal risk is thromboembolism, influenced by patient risk factors and anticoagulation resumption timing. Andexanet has shown better hemostatic outcomes compared to PCCs but carries a higher thromboembolic risk.
- Strategies Under Investigation: Investigational reversal strategies include ciraparantag, which binds DOACs; new factor Xa variants like VMX-C001 that bypass factor Xa inhibition; and extracorporeal hemadsorption. New anticoagulants targeting factor XIa may have lower bleeding risks than current DOACs.
- Lab testing: Should not delay clinical assessment of life-threatening bleeding. aPTT, PT, and thrombin time can be prolonged with high concentrations of DOACs, but lack sufficient sensitivity to guide reversal decisions. The guidelines also advocate for more widespread DOAC testing availability and timeliness.
- Management for Urgent Surgery: For emergency surgery, reversal may be required, whereas in urgent surgery, reversal may be deferred/postponed based on DOAC levels or timing of last dose. Guidelines recommend APCC use for dabigatran reversal if idarucizumab is unavailable and PCCs for reversal of oral factor Xa-inhibitors when andexanet is unavailable.
- Administration considerations: Hospitals should develop protocols for DOAC-related bleeding management, considering risks, benefits, and costs. A rapid response team may enhance outcomes, as timely intervention is crucial. Idarucizumab and andexanet require refrigeration and pharmacy reconstitution, while PCCs can be stored at room temperature. Rapid access to these agents in ED and OR settings is essential.
How will this affect my practice?
As DOAC use climbs, ED physicians like myself will continue to see DOAC-related serious bleeding events. For me, the guideline provides a great review that reinforces the importance of understanding indications and best use of reversal agents for managing these events. It also highlights the need to stay updated on evolving reversal strategies and new anticoagulants, which could impact future clinical decision-making and patient outcomes.
Source
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2024 Oct;22(10):2889-2899. doi: 10.1016/j.jtha.2024.07.009. Epub 2024 Jul 17. PMID: 39029742
